Publications 2006-2009


Duprez DA, Kuller LH, Tracy R, Otvos J, Cooper DA, Hoy J, Neuhaus J, Paton NI, Friis-Moller N, Lampe F, Liappis AP, Neaton JD for the INSIGHT SMART Study Group.Lipoprotein particle subclasses, cardiovascular disease and HIV infection.
Atherosclerosis 2009; 207(2):524-9.article

Grund, B, Neuhaus J, Phillips A; INSIGHT SMART Study Group. Relative risk of death in the SMART study.
Lancet Infect Dis. 2009 Dec;9(12):724-5.article

Neuhaus J et al. Markers of inflammation, coagulation and renal function are elevated in adults with HIV infection.
J Infect Dis; in press. article

Neuhaus J et al. Risk of all-cause mortality associated with non-fatal AIDS and serious non-AIDS events among adults infected with HIV.
AIDS; in press. article

Duprez DA, Kuller LH, Tracy R, Otvos J, Cooper DA, Hoy J, Neuhaus J, Paton NI, Friis-Moller N, Lampe F, Liappis AP, Neaton JD for the INSIGHT SMART Study Group. Lipoprotein particle subclasses, cardiovascular disease and HIV infection.
Atherosclerosis 2009; doi:10.1016/j.atherosclerosis.2009.05.001. article

Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, Martinez E, Reiss P, Visnegarwala F, Carr AD for the INSIGHT SMART body composition substudy group. Continuous antiretroviral therapy decreases bone mineral density.
AIDS 2009; 23:1519-1529. article

Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M for the INSIGHT SMART study group. Interruption of antiretroviral therapy is associated with increased plasma cystatin C.
AIDS 2009; 23:71-82. article

Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN for the INSIGHT SMART Study Group. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.
J Infect Dis 2009; article


Burman W, Grund B, Neuhaus J, Douglas J Jr, Friedland G, Telzak E, Colebunders R, Paton N, Fisher M, Rietmeijer C for the SMART Study Group and INSIGHT. Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trial.
J Acquir Immun Defic Synd 2008; 49:142-150.article

Burman WJ, Grund B, Roediger MP, Friedland G, Darbyshire J, Wu AW for the SMART Study Group. The impact of episodic CD4 cell count-guided antiretroviral therapy on qualify of life.
J Acquir Immun Defic Synd 2008; 47(2):185-193. article

Carr A, Grund B, Neuhaus J, El-Sadr WM, Grandits G, Gibert C, Prineas RJ for the SMART Study Investigators. Asymptomatic myocardial ischaemia in HIV-infected adults.
AIDS 2008; 22(2):257-267.article

Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Huppler Hullsiek K, Stephan C, Lundgren J on behalf of the SMART Study Group. Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.
AIDS 2008; 22:2279-2289.article

Gordin FM, Roediger MP, Girard PM, Lundgren JD, Miro JM, Palfreeman A, Rodriguez-Barradas MC, Wolff MJ, Easterbrook PJ, Clezy K, Slater LN.. Pneumonia in HIV-infected persons: Increased risk with cigarette smoking and treatment interruption.
Am J Respir Crit Care Med 2008; 178(6):630-636. Epub 2008 Jul 10..article

Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD for the INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.
PLoS Med 2008; 5(10):e203. doi:10.1371/journal.pmed.005. article

Lifson AR and the INSIGHT Cause of Death Writing Group: Belloso WH, Carey C, Davey RT, Duprez D, El-Sadr WM, Gatell JM, Gey DC, Hoy JF, Krum EA, Nelson R, Nixon DE, Paton N, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson J, Worley J. Determination of the underlying cause of death in three multicenter international HIV clinical trials.
HIV Clin Trials 2008; 9:177-185. article

Neaton JD, Grund B. Earlier initiation of antiretroviral therapy in treatment-naïve patients: implications of results of treatment interruption trials.
Current Opinion in HIV and AIDS 2008; 3:112-17. article

Phillips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman WJ, Williams I, Drummond F, Duprez D, Belloso WH, Goebel F-D, Grund B, Hatzakis A, Vera J, Lundgren JD. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial.
Antivir Ther 2008; 13:177-187. article

Phllips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS.
AIDS 2008; 22:2409-2418. article

SMART Study Group. Inferior clinical outcome of the CD4+ cell count guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ cell counts and HIV RNA levels during follow-up.
J Infect Dis 2008; 197:1145-1155. article

SMART Study Group. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy, a randomized trial.
Ann Int Med 2008; 149:289-299. abstract

See also: Gupta SK. Letter to Editor and Response. (editorial)
Ann Int Med 2009; 1509(4):282-283.

SMART Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.
J Infect Dis 2008; 197:1133-1144. article

See also: Hughes MD, Ribaudo HR. The search for data on when to start treatment for HIV infection. (editorial)
J Infect Dis 2008; 197:1084-1086. article

SMART/INSIGHT and D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.
AIDS 2008; 22:F17-F24. article

Tedaldi E, Peters L, Neuhaus J, Puoti M, Rockstroh J, Klein MB, Dore GJ, Mocroft A, Soriano V, Clotet B, Lundgren JD for the SMART Study Group and International Network for Strategic Initiatives in Global HIV Trials (INSIGHT). Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the Strategic Management of Antiretroviral Therapy (SMART) study.
Clin Infect Dis 2008; 47:1468-1475. article

See also: Wyles DL. Hepatitis virus coinfection in the Strategic Management of Antiretroviral Therapy (SMART) study: A marker for nonliver, non-opportunistic disease mortality. (editorial)
Clin Infect Dis 2008; epub 27 October. article

Wendler D, Krohmal B, Emanuel EJ, Grady C for the ESPRIT Group. Why patients continue to participate in clinical research.
Arch Int Med 2008; 168(12):1294-1299. article


ESPRIT Research Group (Fox Z, Antunes F, Davey R, Gazzard B, Klimas N, Labriola A, Losso M, Neaton JD, Phillips AN, Ruxrungtham K, Staszewski S, Weiss L, Lundgren JD). Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/microL who were assigned to 7.5 MIU interleukin-2.
HIV Med 2007; 8(2):112-123. article

Ellis KJ, Grund B, Visnegarwala F, Thackeray L, Miller CG, Chesson CE, El-Sadr W, and Carr A for the Strategies for Management of Anti-Retroviral Therapy (SMART) Study Group. Visceral and subcutaneous adiposity measurements in adults: Influence of measurement site.
Obesity 2007; 15(6):1441-1447. article

Lewis DE, Gross KL, Diez MM, Martinez ML, Lukefahr HN, Kozinetz CA, Arduino RC. CD8 apoptosis may be a predictor of T cell number normalization after immune reconstitution in HIV.
J Transl Med 2007; 5(1):9. article

Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, Hidalgo J, Lortau L, Neaton JD, Tambussi G, and Abrams DI. Risk of cancers during interrupted antiretroviral therapy in the SMART study.
AIDS 2007; 21:1957-1963. article


Lifson AR, Rhame FS, Belloso WH, Dragsted UB, El-Sadr WM, Gatell JM, Hoy JF, Krum EA, Nelson R, Pedersen C, Pett SL, Davey RT Jr. Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials.
HIV Clin Trials 2006; 7(3):125-141. article

Mocroft A, Neaton J, Bebchuk J, Staszewski S, Antunes F, Knysz B, Law M, Phillips AN, Lundgren JD for the EuroSIDA and ESPRIT Study Groups. The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era.
Clinical Trials 2006; 3:119-132. article

Pace C, Grady C, Wendler D, Bebchuk JD, Tavel JA, McNay LA, Forster HP, Killen J, Emanuel EJ for the ESPRIT Group. Post-trial access to tested interventions: The views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study.
AIDS Research and Human Retroviruses 2006; 22(9):837-841. article

Pett SL, Wand H, Law MG, Arduino R, Lopez JC, Knysz B, Pereira LC, Pollack S, Reiss P, Tambussi G for the ESPRIT Research Group. Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial (ESPRIT): Geographical and gender differences in the baseline characteristics of participants.
HIV Clin Trials 2006; 7(2):70-85. article

SMART Study Group. CD4+ count-guided interruption of antiretroviral treatment.
N Engl J Med 2006; 355:2283-2296. article

See also: Currier JS, Baden LR. Getting smarter - the toxicity of undertreated HIV infection. (editorial)
N Engl J Med 2006; 355:2359-2361. article

Youle M, Emery S, Fisher M, Nelson M, Fosdick L, Janossy G, Loveday C, Sullivan A, Herzmann C, Wand H, Davey RT Jr, Johnson MA, Tavel JA, Lane HC. A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: The UK-vanguard study.
PLoS Clin Trials 2006; 1(1):e3. article